Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.
Isacco DesideriG FrancoliniV ScottiD PezzullaC BecheriniF TerzianiC Delli PaoliE OlmettoL VisaniI MeattiniD GretoP BonomoM LoiB DettiL LiviPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2018)
Our data showed significant advantage for oligoprogressive patients treated with RT during nivolumab therapy. No safety alert emerged. These results underline the potential synergistic effects of RT and Immune therapy combination. Our analysis prompts further prospective studies exploring the benefit of integrated treatment strategies.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- small cell lung cancer
- squamous cell carcinoma
- chronic kidney disease
- early stage
- peritoneal dialysis
- palliative care
- prognostic factors
- radiation therapy
- electronic health record
- radiation induced
- machine learning
- patient reported outcomes
- deep learning
- human health
- patient reported
- rectal cancer